These are slides for the sales team.

1. THOMSON REUTERS CORTELLISTM
CLINICAL TRIALS INTELLIGENCE
CLEARLY CORTELLIS
Created by Michael Passanante

2. 2

3. 3

4. Cortellis Clinical Trials Intelligence…
• Cortellis Clinical Trials Intelligence is the most powerful resource to
accelerate clinical trial development decisions and portfolio strategy.
• Cortellis Clinical Trials Intelligence is the premiere clinical trials
competitive intelligence offering, covering drugs, medical devices and
biomarkers, from trials around the world
4

5. Why Thomson Reuters?
• The industry’s leading provider of high-quality & authoritative Life
Sciences content that is meticulously curated
• Already your strategic partner for competitive and scientific
intelligence
• The only solution provider who can truly integrate a wide range of
knowledge areas across our knowledge areas AND with your own
information
Offering an affordable and accessible clinical trials intelligence solution that’s
available to your enterprise, is truly integrated and very easy to use
5

6. Why Thomson Reuters?
• Longstanding Assets and Capabilities
– Analyzing clinical outcomes from scientific literature since 1964
• Derwent Drug File (DDF) is largest drug literature database available
and provides full abstracts of the article
– Performing clinical benchmarking services since 1998
• Supporting clinical development in the optimization of global clinical
performance metrics, analysis, and trending through its CMR
business
– Abstracting clinical trials from literature and meetings since 2000
• Scientific expertise from the Integrity editorial team
– Indexing and Integrating clinical trials from registries and press
release since 2007
• Commercial and competitive expertise from the Thomson Reuters
Pharma editorial team
Quality Focus + Assets + Experience = Best-in-class Solution
6

7. 7

8. Rely on our expertly abstracted and peer-reviewed
content that’s assembled by a global team of
scientific editors
• Over 140,000 US and global trials
from more than 20,000 sources
covering Drugs, Biologics,
Devices, Biomarkers
• More than 200,000 press releases
indexed to clinical trial types or
events
• 220,000 fully abstracted literature
articles on clinical outcomes and
2.25 million articles related to
clinical development
• Over 21,000 meeting abstracts
and over 8,000 conference reports
8

9. Rely on our expertly abstracted and peer-reviewed
content that’s assembled by a global team of
scientific editors
• Patient segment, eligibility and
endpoints filters/indexes
• Free research service
• Integration potential with more
than 15 other best-in-class
content offerings including
event transcripts, biomarkers,
drug pipeline, patents,
drug approvals, disease
briefings, deals, trial
regulations, PK data and more
9

10. Rely on our expertly abstracted and peer-reviewed
content that’s assembled by a global team of
scientific editors
• Two Packages available to
match your needs
• US trials
• Global Trials
10

11. 11

12. Cortellis for Clinical Trials Intelligence
supports personalized medicine strategies
• Personalized medicine is
becoming an integral part
of the R&D process
• A 50% increase in
personalized R&D
investment is anticipated
between 2010 – 2015
• Cortellis for Clinical Trials
Intelligence supports
research into stratified
patient populations and
outcomes
http://phrma.org/sites/default/files/2435/phrmapipelinereportfinal11713.pdf12

13. Best -in-class web portal technology offers dozens
of filters for enhanced searching plus robust alerting
and exporting features
• Powerful indexes for
 disease therapy areas
 actions and drug classes
 when interventions go into a
therapy area for the first time
 patient segment and eligibility
criteria
 endpoints
 biomarkers
 combination therapies
 trial designs
 adverse events
13

14. Best -in-class web portal technology offers dozens
of filters for enhanced searching plus robust alerting
and exporting features
• Locate ‘proof of concept’ trials –
the first small patient trials with
efficacy endpoints or efficacy
biomarkers
• Ability to find or analyze trials
by the drug intervention’s drug
class, mechanism of action or
technology
• Granular quantified outcomes
for assessment of competitive
landscape, patient response
and CER
14

15. Best -in-class web portal technology offers dozens
of filters for enhanced searching plus robust alerting
and exporting features
• Robust export options (export
5,000 records at once)
• iPad compatible web portal
• Customizable views and
alerting features
• Get help instantly with live chat
and online resources
15

16. 16

17. Dynamic visual analytic tools reduce time spent
compiling and analyzing clinical trial information
• Visualizations show the
distribution of indication,
intervention,
sponsor, phase, recruitment
status, country design, and
active control
• Dynamically updated Spotfire
visualization delivers insight
into trial timelines and disease
segmentation
• Visualizations can be saved in
PowerPoint format so findings
can be shared with senior
management and updated
easily
17

18. 18

19. How does Cortellis Clinical Trials
Intelligence compare?
Feature Competitor
Cortellis for Clinical
Trials Intelligence
Extensive filtering and
searching on 30+ indexes
No 
Exporting large recordsets
(thousands of records)
No 
Modern interface No 
Programmatic Access / API No 
Dynamic Analytics / Visuals
Included
No 
Full text searchable Press
Releases, Literature Abstracts,
Meeting Abstracts
No 
Includes device and biomarker
trials
No 
19

20. How does Cortellis Clinical Trials
Intelligence compare?
Global trials and
outcomes data
Expertise
Support
Detailed
Site &
Investigator
Information
Cortellis for
Clinical Trials
Intelligence
Competitor
(add-ons may be
required)
Scientific Expertise
Coverage
Your Content
More Content
Decision Support
Strongest for scientific insights
supporting preclinical and clinical
development
All Trials – drug, biologic, device,
biomarker
Integrated & securely hosted
proprietary knowledge
More breadth of integrated knowledge
areas; more clinical trial indexes
Dynamically updated visualizations &
analytics
20

21. 21

22. Flexible access to our clinical content or yours
through the Cortellis web portal or any interface
leveraging our APIs
• Informatics solutions enable
you to easily integrate our
content into other applications
and platforms in real-time
through a suite of APIs
(Application Programming
Interface)
• Information integration solutions
let you incorporate your
proprietary content and custom
annotations with Thomson
Reuters intelligence on the
Cortellis platform
22

23. Clinical Professional Services –
Providing customized solutions to clients leveraging
our unique blend of content, technology, and expertise
Technology
Expertise
Content
• Clinical trial design
– patient stratification techniques,
recommended endpoints
• Clinical trial planning
– site selection and future disease
landscaping and epidemiology
• Strategic decision making
– entering or exiting disease area decision
support, R&D organizational consulting
• Custom Analytics & Visualizations – to
drive strategic decision making around
drug safety, trial timelines, and
competitive trials
23

24. APPENDIX
24

25. Trusted Content
Reliable
Our investigational drug content is trusted by 100% of the top twenty
pharmaceutical companies globally and hundreds of other firms in the
drug discovery arena
We use six-sigma methodology to measure and track the quality of the
content processed by our editorial teams
Precise
Our experts understand drug discovery - all of our editors have a
scientific background in subjects including chemistry, biochemistry,
biotechnology, biology, pharmacology, and medicine
Every drug in active, commercial development from 1994 onwards is
covered and no information is removed from the database
Clear
Content is derived from a wide variety of sources and is carefully
selected, reviewed, and indexed to ensure optimal search results with
unmatched depth and breadth
Our standardized taxonomies deliver information so it is useful and
consistent
25

26. Available content in
Cortellis Clinical Trials Intelligence
Over 130,000 global clinical trials
US or Global Coverage Options
Drugs, Biologics, Devices, Biomarkers
Over 21,000 meeting abstracts and over 8,000 conference
reports
More than 200,000 press releases indexed to clinical trial
types or events
Clinical Trials
Literature
Conferences
Press Releases
Search over 15,000 biomedical analyst call transcripts,
indexed to drugs
Event Transcripts
All counts as of April 2012
Outcome searching stretching back to the 1960s
2.25+ fully abstracted articles
220,000 articles related to clinical trial outcomes
26

27. THOMSON REUTERS CORTELLIS
We are the world’s leading source of intelligent information for businesses and professionals,
combining industry expertise with innovative technology to deliver critical information to leading
decision makers.
27

28. Who We Are
Thomson Reuters is the largest provider of intelligent
information to business and professional customers in the
world. Generating a total revenue of over $13.0bn in 2012.
Largest Provider of
Intelligent Information
We operate in 300 cities in over 100 countries across the
world.
True Global
Presence
Across our business, we have varied and vast expertise,
including 14,300 legal experts; 9,300 financial experts; 4,800
tax and accounting experts; 4,500 healthcare and scientific
experts and 2,800 seasoned journalists.
For Professionals,
By Professionals
Named #40 in the BusinessWeek 2009 ranking of the 100
Best Global Brands.
Ranked #2 for Financial Data Services in Fortune’s 2010
Most Admired Companies list
Strong Brand
28

29. Additional Cortellis
Knowledge Areas Available
Preclinical studies;
PK/Metabolism
studies (SI)
535K Pharmacokinetic (PK) and 1.3 million experimental pharmacology
records (PD).
Patents 2.4 million biomedical and medicinal chemistry
Biomarkers Over 19,000 biomarkers
Deals
32,000 deals provides insight into how deal terms relate to clinical
results
Disease Briefings More than 130 detailed reports on pivotal disease areas
Pipeline Integration with our leading drug pipeline of 47,000 drugs
Clinical Trial
Regulations (RI)
4,500 global guidelines and regulations from 63 countries
Drug Approvals 16,000 drug approval packages and approved labels
Event Transcripts
15,000 transcripts from public pharmaceutical and biotech companies’
investor conference calls
29

30. TECHNICAL INFORMATION
30

31. The Power of Integrated Information
Preclinical Studies
Targets & Pathways
Regulatory
Deals
Disease briefings
Patents
Financial
Clinical
Trials
BD&L, CI
Clinical Dev
Clinical Dev
Reg Affairs
BD&L
Brand Mgrs
BD&L, Legal
BD&L
CI
Competitive Landscaping
Leverage Science in Trial Design
Select Better Populations & End Points
Inform Regulatory Strategy
Identify partnership & out-licensing opps
Portfolio Prioritization
Identify in-licensing opps, find IP infringe
Assess Clinical Program financial fitness
Real-time Decisions based on breaking news
Core
Knowledge
More
Knowledge
Supporting
Areas
Making
Decisions
31

32. Sources for trials data
• Clinicaltrials.gov
• International registries
• Company registries
• Company websites
• Biomedical literature
• Medical & Investor meetings
• Press releases
• Clinicalstudyresults.org
• Other Drug Pipeline Sources
• Clinicastudyresults.org (US)
• UK registry
• Australia/NZ registry
• Chinese registry
• Indian registry
• EudraCT (EMA’s registry)
• ISRCTN (pan European registry)
• Japan - UMIN CTR
• Japan - JapicCTI
• Japan - JMACCT CTR
• Netherlands registry
• Brazilian registry
• Korean registry
• Iranian registry
Includes

33. Editorial Scope
• All drug and biologic trials
• All treatment and prophylactic medical device trials
• All biomarker trials
• All therapeutic areas
33

34. Indexes / filters
34
• Standard Indexes
– All typical indexes includes
– Available for both filtering and analytics
– Includes indication, mechanism of action, sponsor, phase, etc.
• Additional Unique Indexes Available:
• Patient segment • First time drug in indication
• Eligibility criteria • Sponsor owns drug
• Endpoints • Source type
• Treatment arms (Dec) • Active control
• Adverse events • Quantified outcomes (Dec)
• Biomarkers
• Novel designs (e.g. adaptive) (Dec)

35. USE CASES
35

36. Top 10 Use Cases
• Competitive Intelligence
– Who else is in clinical development in my area, and how will they
compete with me? What exact indication/patient segment are they
after?
– What endpoints are my competitors going after? What outcomes do
I need to beat, and which can I position against?
– What are the timelines of competing trials? When will competitors be
able to bring products to market, and when will there be least
competitions for the same patients?
– Where are my competing trials occurring? Where should I run my
trials to minimize competition for patients?
36

37. Top 10 Use Cases (cont’d)
• Protocol Design
– What biomarkers are being used to stratify patients; which should
I use?
– What are the active controls I need to gain global acceptance?
– What eligibility criteria can I use to simplify the trial, reduce costs,
increase recruitment, yet gain global approval?
• Clinical Science
– Do the outcomes from competitive phase 1 and 2 trials validate
our ideas about the MoA?
– Why are competitors looking at a certain target in a certain patient
segment?
– What is the clinical validity of a biomarker?
37